InspireMD FDA Approves CGuard Prime, Restoring U.S. Market Access

InspireMD (NSPR) announced FDA approval of CGuard Prime for TCAR, re-entering the U.S. market. Q3 revenue was $2.242M, down 11.1% YoY, with a net loss of $9.762M. The company has $19.246M in cash. Analysts rate NSPR as Buy with a $4.00 target, but Spark's AI rates it Neutral due to weak profitability and cash burn.

Original reporting
Published Nov 12, 2026, 10:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 15, 2026, 5:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$NSPR
Bullish
high confidence
Mentioned
$NSPR
Relevance
8/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$NSPRBullishMed
01

Why it matters

The approval could reverse the recent revenue decline and improve cash flow, but execution risk remains.

02

Market read

Primary regulatory news for a listed micro‑cap; likely short‑term price move.

03

What to watch

Potential reimbursement challenges and competition from established stent manufacturers.

Relevance 8/10Novelty 5/10Timing: today

Background

InspireMD (NSPR) reported third‑quarter results showing a net loss and minimal U.S. revenue after a recall, but highlighted the FDA approval as a catalyst.

Company-level read

Ticker impact

$NSPRBullishHigh confidence
Context

FDA approval of CGuard Prime restores U.S. market access and adds >35,000 procedures annually.

Expected impact

upward pressure as investors price in new product launch and expanded market opportunity

Evidence & confidence

The approval is a primary regulatory event for a micro‑cap medical device maker; such news historically drives short‑term buying.

Market effects

May boost sentiment for the broader carotid stent and vascular device sector.

Positive for U.S. med‑tech stocks, limited global effect.

Low; impact confined to niche medical device market.

Counterpoint

The company’s cash burn and limited U.S. revenue could limit upside despite approval.

Key entities

  • InspireMD

    Medical device maker focused on carotid stent systems.

  • FDA

    U.S. Food and Drug Administration that granted approval.

Related articles

$NSPRHighAI 8/10

InspireMD (NSPR) Q3 2026 Earnings Call Transcript

InspireMD (NSPR) announced FDA approval for its CGuard Prime TransCarotid Stent System, expanding U.S. market access by 40,000 annual procedures. Q3 2026 international revenue grew 9% YoY to $2.2M. The company plans commercial execution and cost alignment, with a 20% workforce reduction. FDA submission for the CGuard Prime 135 CAS delivery system is expected by year-end.

$NSPRLow

InspireMD Inc (NSPR) (Q3 2026) Earnings Call Highlights: FDA Nod for CGuard Prime Reopens

InspireMD (NSPR) reported Q3 2026 revenue of $2.2M, down 11% YoY, with gross margin at 10.7%. The company received FDA approval for CGuard Prime, expecting immediate sales due to pent-up demand. Cash position is $19.2M, with potential $10M from warrant exercises. A workforce reduction cut expenses by 27%. The US market opportunity is expanded by 40,000 annual procedures. No formal guidance was provided.

$NSPRHigh

InspireMD Reports Third Quarter 2026 Financial Results

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 InspireMD Reports Third Quarter 2026 Financial Results - Received FDA approval of CGuard® Prime for Transcarotid Arterial Revascularization (TCAR) procedures, expected to approximately double the U.S. addressable market - - Company to host investor conference call to

$NSPRHighAI 8/10

InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 InspireMD Announces FDA Approval of the CGuard ® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures - Approval doubles the CGuard Prime platform’s total addressable market in the U.S. with additional access to over 35,000 TCAR

$NSPRMed

InspireMD Q2 2026 Earnings: Revenue Misses $1.77 Million Estimate

InspireMD (NSPR) reported Q2 2026 revenue of $1.77M, missing estimates of $2.54M, and a net loss of $0.17 per share, beating expectations. Shares fell 7.06% due to revenue shortfall and U.S. recall impacts. The company expects FDA decisions on key products later in 2026. International revenue rose 21% YoY, while U.S. revenue was negative due to recall-related credits.